Elsevier presents ManRos Therapeutics’ research programmes and strategic plan.

Article by Elsevier

ManRos Therapeutics looks forward to see you at the “Palais du Grand Large” in Saint-Malo, France, from March 28th to April 1st 2017. Over 50 speakers will present the progress of their research work on the DYRK1A kinase, involved in Alzheimer’s disease and Down syndrome.

Conference abstract

Innovative company of the year!

ManRos Therapeutics was elected Innovative company of the year 2016 during the fourth “Victoires de la Bretagne” (Brittany Awards). R-Roscovitine, also known as Seliciclib, was discovered by Dr. Laurent Meijer’s team in a starfish in 1990. This molecule is currently in Phase IIa clinical trial in cystic fibrosis.

Cyclacel and ManRos Therapeutics announce licensing and supply agreement regarding development of R-Roscovitine / Seliciclib in cystic fibrosis

Article by Cyclacel